zg46xikf

Property	Value
?:abstract	OBJECTIVE: We report the findings from the Spanish Society of Neurology\'s NeuroCOVID-19 Registry. METHODS: We performed a multicentre study of patients with neurological manifestations of COVID-19. Participating physicians reported demographic, clinical, and paraclinical data and judged the involvement of COVID-19 in causing neurological symptoms. RESULTS: A total of 233 cases were submitted, including 74 different combinations of manifestations. The most frequently reported were stroke (27%), neuromuscular symptoms (23.6%), altered mental status (23.6%), anosmia (17.6%), headache (12.9%), and seizures (11.6%). The mean age of patients was 61.1 years, with 42.1% being women; a higher proportion of women was recorded among patients with altered mental status, anosmia, and headache. The onset of symptoms differed within categories. Onset of anosmia occurred a mean (standard deviation) of 2.9 (2.5) days after the first general symptom, whereas neuromuscular symptoms appeared after 13.9 (10.1) days. Neurological symptoms were persistent in 33% of patients. General symptoms were present in 97.7% of patients, and results from general laboratory studies were abnormal in 99.4% of patients. Cerebrospinal fluid analysis findings were abnormal in 62.7% of the cases in which this test was performed (n = 51), but positive results for SARS-CoV-2 were only found in one case. CONCLUSIONS: The neurological manifestations of COVID-19 are diverse. Anosmia, myalgia, and headache occur earlier in the course of the disease. Altered mental status, neuromuscular symptoms, and stroke are associated with greater severity. COVID-19 must be incorporated into most clinical and radiological differential diagnoses. COVID-19 may cause persistent and disabling neurological symptoms.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/zg46xikf_hasAnnotation_C0018681> <https://research.tib.eu/covid-19/entity/zg46xikf_hasAnnotation_C0036572> <https://research.tib.eu/covid-19/entity/zg46xikf_hasAnnotation_C0159028> <https://research.tib.eu/covid-19/entity/zg46xikf_hasAnnotation_C0231528> <https://research.tib.eu/covid-19/entity/zg46xikf_hasAnnotation_C0235031> <https://research.tib.eu/covid-19/entity/zg46xikf_hasAnnotation_C0278061> <https://research.tib.eu/covid-19/entity/zg46xikf_hasAnnotation_C1457887> <https://research.tib.eu/covid-19/entity/zg46xikf_hasAnnotation_C3539957> <https://research.tib.eu/covid-19/entity/zg46xikf_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Garc%C3%ADa-Azor%C3%ADn%2C_David%3B_Abild%C3%BAa%2C_Mar%C3%ADa_Jos%C3%A9_Abenza%3B_Aguirre%2C_Mar%C3%ADa_Elena_Erro%3B_Fern%C3%A1ndez%2C_Santiago_Fern%C3%A1ndez%3B_Monc%C3%B3%2C_Juan_Carlos_Garc%C3%ADa%3B_Guijarro%2C_Cristina%3B_Platas%2C_Montserrat_Gonz%C3%A1lez%3B_Delgado%2C_Fernando_Romero%3B_Andr%C3%A9s%2C_Jos%C3%A9_Miguel_L%C3%A1inez%3B_Ezpeleta%2C_David>
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.jns.2020.117283>
?:doi	10.1016/j.jns.2020.117283
?:journal	J_Neurol_Sci
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/28e9a27cefa28f7fbfffc51140b755aa55509072.json
?:pmc_json_files	document_parses/pmc_json/PMC7749644.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7749644>
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/zg46xikf_HAS_C0235031_CAUSES_C5203670>
?:sha_id	<https://research.tib.eu/covid-19/entity/28e9a27cefa28f7fbfffc51140b755aa55509072>
?:source	Elsevier; PMC
?:title	Neurological presentations of COVID-19: Findings from the Spanish society of neurology neuroCOVID-19 registry
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-12-19

Property

Value

?:abstract

OBJECTIVE: We report the findings from the Spanish Society of Neurology\'s NeuroCOVID-19 Registry. METHODS: We performed a multicentre study of patients with neurological manifestations of COVID-19. Participating physicians reported demographic, clinical, and paraclinical data and judged the involvement of COVID-19 in causing neurological symptoms. RESULTS: A total of 233 cases were submitted, including 74 different combinations of manifestations. The most frequently reported were stroke (27%), neuromuscular symptoms (23.6%), altered mental status (23.6%), anosmia (17.6%), headache (12.9%), and seizures (11.6%). The mean age of patients was 61.1 years, with 42.1% being women; a higher proportion of women was recorded among patients with altered mental status, anosmia, and headache. The onset of symptoms differed within categories. Onset of anosmia occurred a mean (standard deviation) of 2.9 (2.5) days after the first general symptom, whereas neuromuscular symptoms appeared after 13.9 (10.1) days. Neurological symptoms were persistent in 33% of patients. General symptoms were present in 97.7% of patients, and results from general laboratory studies were abnormal in 99.4% of patients. Cerebrospinal fluid analysis findings were abnormal in 62.7% of the cases in which this test was performed (n = 51), but positive results for SARS-CoV-2 were only found in one case. CONCLUSIONS: The neurological manifestations of COVID-19 are diverse. Anosmia, myalgia, and headache occur earlier in the course of the disease. Altered mental status, neuromuscular symptoms, and stroke are associated with greater severity. COVID-19 must be incorporated into most clinical and radiological differential diagnoses. COVID-19 may cause persistent and disabling neurological symptoms.

is ?:annotates of